Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECs315
- Development stage
- Unknown
- Lead developer
- Bod Australia
- Modality
- Small Molecules
- Administration
- Sublingual, Oral
01
Overview
ECs315 is a proprietary, full-plant cannabis extract primarily composed of cannabidiol (CBD), developed by Bod Australia Limited. The drug is sourced in collaboration with Swiss botanicals manufacturer Linnea SA and utilizes the patented 'WaferiX' sublingual wafer technology developed by iX Biopharma. This delivery system is designed to enhance the bioavailability and absorption of the phytocomplex compared to traditional oral oil formulations. ECs315 is currently in clinical development, having completed a Phase I study to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers. Its primary therapeutic target is chemotherapy-induced nausea and vomiting (CINV), with potential expansion into indications such as multiple sclerosis, epilepsy, and anxiety.
- Brand names
- Xativa
- Other names
- WaferiXsublingual cannabis waferMedicabilis sublingual wafer
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on ECs315.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECs315.